Time to First Tumor Progression as Outcome Predictor of a Second Trasuzumab-Based Therapy beyond Progression in HER-2 Positive Metastatic Breast Cancer
Giulio Metro(University of Perugia), Alessandra Fabi(Agostino Gemelli University Polyclinic), Teresa Gamucci, Mariangela Ciccarese(Ospedale Vito Fazzi), Gaetano Lanzetta(IRCCS Istituto Auxologico Italiano), Francesco Cognetti(Apple (Israel)), Donatello Gemma, Paola Papaldo(Cancer Institute (WIA)), Diana Giannarelli(Agostino Gemelli University Polyclinic), Emanuela Magnolfi(Accademia di Belle Arti di Frosinone), Vito Lorusso(Ospedale Vito Fazzi), Marcella Mottolese
Cited by 11
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
|Annals of Oncology|2016|398